22-09-2023 | Human Papillomavirus | Research
Clinical data, survival, and prognosis of 426 cases of oropharyngeal cancer: a retrospective analysis
Published in: Clinical Oral Investigations | Issue 11/2023
Login to get accessAbstract
Objective
To determine factors influencing survival and prognosis of HPV-related and non-related oropharyngeal cancer.
Methods
Subjects were determined from the three hospitals in Anhui province of China between 2015 and 2020. Paraffin-embedded specimens from participants’ tissues were analyzed, and the subjects were classified as P16 + and P16 − cases using immunohistochemical staining for P16 protein.
Results
A total of 426 patients with oropharyngeal cancer were recruited in this study; 108 cases were found to be P16 + . The subjects were treated with the three regimens: surgery/radiotherapy/chemotherapy (SRCT), radiotherapy/chemotherapy (RCT), and surgery/chemotherapy (SCT). There were no statistically significant differences in the survival rates within the P16 + or P16 − groups between the three treatment regimens (P > 0.05). The 1-, 3-, and 5-year survival rates for P16 + and P16 − groups were statistically different (P < 0.05). Multivariate analysis showed that age, physical health status, smoking, and alcohol abuse were independent risk factors affecting the prognosis of P16 + cases, while pathological grading and TNM staging were independent risk factors affecting the P16 − cases.
Conclusion
The etiology, pathogenesis, survival status, and prognostic factors of HPV-related oropharyngeal cancer are very different from those of traditional oropharyngeal cancer. Thus, HPV-related oropharyngeal cancer could be classified as a separate type of disease. This distinction could be of great significance for treatment, prevention, and prognostication of oropharyngeal cancer.